Greg Zante - Apr 17, 2023 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role
Chief Financial Officer
Signature
/s/ Michael Morneau as Attorney-in-Fact
Stock symbol
VKTX
Transactions as of
Apr 17, 2023
Transactions value $
-$51,975
Form type
4
Date filed
4/18/2023, 07:07 PM
Previous filing
Apr 13, 2023
Next filing
Jan 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VKTX Common Stock, par value $0.00001 per share Options Exercise $98K +7.5K +5.02% $13.07 157K Apr 17, 2023 Direct F1
transaction VKTX Common Stock, par value $0.00001 per share Sale -$150K -7.5K -4.78% $20.00 149K Apr 17, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VKTX Stock Option (Right to Buy) Options Exercise $0 -7.5K -100% $0.00* 0 Apr 17, 2023 Common Stock 7.5K $13.07 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 One-third of the shares subject to the option vested on the grant date and one-third of the shares subject to the option vested on each one year anniversary of the grant date of August 31, 2018.